Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00513214 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Xoma (US).
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT00513214 is a Phase 1 study that has completed, run by Xoma (US). The registered enrollment target is 68 participants.
The verdict
NCT00513214, a Phase 1 study, has completed, sponsored by Xoma (US).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of XOMA 052 in subjects with stable Type 2 Diabetes Mellitus (T2D). The study is a dose-escalation study designed to evaluate route of administration (intravenous or subcutaneous), doses, and dosing regimens for future studies.
Interventions
- DRUG Placebo
- DRUG XOMA 052
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2007-07 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00513214
The ClinicalTrials.gov registry entry for NCT00513214 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xoma (US), which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00513214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00513214 about?
NCT00513214 is a clinical study titled "Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of XOMA 052 in subjects with stable Type 2 Diabetes Mellitus (T2D). The study is a dose-escalation study designed to evaluate route of administration (intravenous or subcutaneous), doses, and dosing regimens for future st...
What is the current status of trial NCT00513214?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2007-07. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00513214?
The interventions under investigation include: Placebo (DRUG), XOMA 052 (DRUG).
Who is sponsoring clinical trial NCT00513214?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.